ÂÜÀòÂÒÂ×

Nick Robbins-Cherry has a diverse and extensive work experience in financial and leadership roles. Nick is currently serving as the Chief Financial Officer at Epsilogen Ltd since February 2023. Prior to this, they worked as the Chief Financial Officer at Ixaka from October 2021 to February 2023, where they played a key role in the development of cell and gene therapy technologies.

Before joining Ixaka, Nick served as the Chief Financial Officer at Vorboss from September 2020 to August 2021. Nick also held the position of Chief Financial Officer at Senzer Limited from November 2019 to November 2020.

Nick's career includes significant achievements as the Chief Financial Officer at Midatech Pharma PLC from February 2014 to October 2019. During their tenure, they successfully completed the company's IPO on AIM, acquired Q Chip Limited, and facilitated a NASDAQ dual-listing which led to the acquisition of DARA BioSciences Inc.

Prior to their roles at Midatech Pharma PLC, Nick worked as the Finance and Commercial Director at The Marketing Practice from January 2013 to January 2014. Nick also held positions of Finance Director and M&A Manager at CACI Ltd from April 2010 to January 2013 and February 2008 to March 2010, respectively.

Nick's earlier career includes roles as the Finance Director at Invocom from February 2001 to February 2008, Finance Director at LifeGard Technologies Ltd from April 2000 to February 2001, and Financial Controller and Special Projects Manager at Johnson & Johnson Limited, Janssen-Cilag Pharmaceuticals from October 1998 to April 2000.

Nick Robbins-Cherry earned a BSc degree in Pharmacology from the University of Bath, which they attended from 1989 to 1992. Nick later pursued an MBA from Henley Business School, completing it from 2006 to 2009.